STX is a commercial-stage company delivering specialty products that address patients’ unmet medical needs, with an initial focus on treating iron deficiency (ID) with ferric maltol. STX’s strategy is to out-license its products for commercialisation. On 8 January, STX announced a development and commercialisation deal in China with Beijing Aosaikang Pharmaceutical Co (ASK Pharm), further validating this approach. In 2019, the FDA approved this drug for a broad indication, opening up a US market currently worth more than $1bn p.a. A US partnership deal is expected in 2020 and will be transitional for STX.
Download the full reportIf you'd like to be introduced to the team at Shield Therapeutics Plc, get in touch.
Request a meeting